Trial Profile
A Pilot Phase I/II Study to Evaluate the Effects of Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients With Biochemical Relapse
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Prednisone (Primary) ; Sunitinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 30 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 22 Apr 2009 New trial record